Where Einstein Meets Edison

Bridging Beauty and Science: Inspiring an Unconventional Path

Bridging Beauty and Science: Inspiring an Unconventional Path

Apr 19, 2013

Career choices classically result in anything but a clear, direct trajectory. Yet, an inherent stigma is many times associated with changing fields or exploring diverse work experiences. If startups are encouraged to pivot during their development process, why is the opposite not true for individuals? There is something to be said about the person who follows an...

Pros and Cons of the Preclinical IPO

Pros and Cons of the Preclinical IPO

Dec 7, 2012

Back in January, Cambridge, MA, cancer therapeutic developer Verastem ($VSTM) made its initial public offering (IPO) and raised $55M in the process.  It was not a monumental IPO success by biopharma standards, but what made the event noteworthy was that Verastem hadn’t yet filed an IND for its lead drug candidate, the first step in the FDA regulatory process...

Innovation in Pharma Part IV: What comes next?

Innovation in Pharma Part IV: What comes next?

Apr 1, 2012

This is part IV of a series of articles on innovation in Pharma based on an interview with Jose Carlos Gutierrez Ramos, the man in charge of revolutionizing drug discovery at Pfizer. In part I we establish the difficulties facing Big Pharma as brand name drugs go off patent and pipelines run dry. Pfizer is trying to rewire the relationships between pharma,...

Innovation in Pharma Part III: Turning biotech relationships from zero-sum to win-win-win

Innovation in Pharma Part III: Turning biotech relationships from zero-sum to win-win-win

Mar 29, 2012

This is part III of a series of articles on innovation in Pharma based on an interview with Jose Carlos Gutierrez Ramos, the man in charge of revolutionizing drug discovery at Pfizer. In part I we establish the difficulties facing Big Pharma as brand name drugs go off patent and pipelines run dry. Pfizer is trying to rewire the relationships between pharma,...

Innovation in Pharma Part II: Rethinking academic collaborations

Innovation in Pharma Part II: Rethinking academic collaborations

Mar 29, 2012

This is part II of a series of articles on innovation in Pharma based on an interview with Jose Carlos Gutierrez Ramos, the man in charge of revolutionizing drug discovery at Pfizer. In part I we established the difficulties facing Big Pharma as brand name drugs go off patent and pipelines run dry. Pfizer is trying to rewire the relationships between pharma,...

Innovation in Pharma Part I: “A New Fabric of Biomedicine”

Innovation in Pharma Part I: “A New Fabric of Biomedicine”

Mar 29, 2012

The Pfizer research facility lies at the end of a long cul-de-sac just beyond the Alewife T station in North Cambridge. The road winds past laboratory buildings peppered with industrial loading docks and warehouses fed by freight train tracks. The blue Pfizer logo is everywhere. I’m here to meet with Jose Carlos Gutierrez Ramos, the Senior Vice President...